research Vitamin D and Alopecia Areata: Possible Roles in Pathogenesis and Potential Implications for Therapy
Vitamin D might be involved in the development of alopecia areata and could help in its treatment.
Search
for
Sort by
Research
120-150 / 1000+ resultsresearch Birth, Life, and Death of the MAGE3 Hypothesis of Alopecia Areata Pathobiology
The MAGE3 hypothesis for alopecia areata did not lead to a significant breakthrough.
research Ruxolitinib Protects Skin Stem Cells And Maintains Skin Homeostasis In Murine Graft-Versus-Host Disease
Ruxolitinib helps protect skin stem cells and keeps skin healthy in mice with skin GVHD.
research Oral Lichen Planus: A Chronic Systemic Disease with Immune-Mediated Pathogenesis
Oral lichen planus is a chronic disease causing mouth discomfort and sometimes needs immunosuppressive treatment.
research The JAK/STAT Signaling Pathway: From Bench to Clinic
The JAK/STAT pathway is important in cell processes and disease, and JAK inhibitors are promising for treating related conditions.
research Ritlecitinib And Brepocitinib Demonstrate Significant Improvement In Scalp Alopecia Areata Biomarkers
Two drugs, ritlecitinib and brepocitinib, improved scalp hair loss condition markers.
research Role of Janus Kinase Inhibitors in the Treatment of Alopecia Areata
Janus kinase inhibitors show promise in treating alopecia areata but need better topical formulations.
research Calreticulin: Non-Endoplasmic Reticulum Functions in Physiology and Disease
Calreticulin has roles in healing, immune response, and disease beyond its known functions in the endoplasmic reticulum.
research Update on the Dermatologic Use of Systemic Glucocorticosteroids
Systemic glucocorticosteroids are a primary treatment for various skin conditions but require careful management due to potential side effects and relapses.
research An Important Role of Cutaneous Lymphatic Vessels in Coordinating and Promoting Anagen Hair Follicle Growth
Skin lymphatic vessels are essential for hair growth.
research Hair Growth in a Patient with Alopecia Areata on Tocilizumab
A woman with alopecia regrew her hair after taking a higher dose of tocilizumab.
research Dermatologic Adverse Events from Cancer Treatments
Cancer treatments can cause skin-related side effects that may affect patient quality of life and require changes in treatment.
research Experience with Oral Tofacitinib in Severe Alopecia Areata with Different Clinical Responses
Oral tofacitinib helped regrow hair in over half of the patients with severe alopecia, but relapses and side effects were common.
research Alopecia Universalis After Alemtuzumab Treatment for Multiple Sclerosis: A Two-Year Follow-Up of Two Patients
Two patients developed complete hair loss after Alemtuzumab treatment for MS, with no regrowth after two years.
research Alopecia Areata: A Comprehensive Review of Pathogenesis and Management
New treatments for Alopecia Areata show promise but need to be more effective and affordable.
research Alopecia Universalis in an Adolescent Successfully Treated with Upadacitinib: A Case Report and Review of the Literature on the Use of JAK Inhibitors in Pediatric Alopecia Areata
A 14-year-old girl with severe hair loss regrew her hair using upadacitinib.
research Correlation Between Serum Granulysin Level and Clinical Activity in Patients with Alopecia Areata Before and After Tofacitinib Therapy
Higher granulysin levels in the blood are linked to more severe hair loss in alopecia areata patients, and these levels decrease after effective treatment.
research Oral Ruxolitinib Induces Hair Regrowth in Patients with Moderate-to-Severe Alopecia Areata
Ruxolitinib effectively regrows hair in most patients with severe hair loss.
research Rapid Skin Repigmentation on Oral Ruxolitinib in a Patient with Coexistent Vitiligo and Alopecia Areata
A man with vitiligo and alopecia saw quick skin and hair improvement with ruxolitinib, but skin color gains were lost after stopping treatment.
research Lichen Planus
Lichen planus is a skin condition that can resolve on its own, is linked to hepatitis C, and increases the risk of skin cancer.
research Alopecia Areata: A Multifactorial Autoimmune Condition
Alopecia areata is an autoimmune disease causing patchy hair loss, often with other autoimmune disorders, but its exact causes are unknown.
research Tofacitinib for the Treatment of Alopecia Areata and Variants in Adolescents
Tofacitinib helped regrow hair in most adolescents with alopecia areata, but more research is needed.
research Rhodococcus Equi: Clinical Manifestations, Virulence, and Immunity
Rhodococcus equi causes severe pneumonia in young foals, and effective vaccines are needed due to foals' weak immune responses.
research Treatment of Alopecia Universalis with Topical Janus Kinase Inhibitors – A Double Blind, Placebo, and Active Controlled Pilot Study
Topical JAK inhibitors may help treat alopecia universalis by promoting hair regrowth.
research Fatal Toxic Epidermal Necrolysis Associated With Cetuximab in a Patient With Colon Cancer
A cancer patient died from a severe skin reaction after taking the drug cetuximab.
research Lack of Efficacy of Apremilast in 9 Patients with Severe Alopecia Areata
Apremilast did not work for treating severe alopecia areata.
research Evaluation of the Efficacy of Transdermal Drug Delivery of Calcipotriol Plus Betamethasone Versus Tacrolimus in the Treatment of Vitiligo
Calcipotriol plus betamethasone with microneedling works better than tacrolimus for treating vitiligo.
research Rebound Effect Associated with JAK Inhibitor Use in the Treatment of Alopecia Areata
Stopping JAK inhibitor treatment for hair loss can lead to worse hair loss than before the treatment.
research Immunomodulators in the Treatment of Cutaneous Lymphoma
Immunomodulatory therapies are effective for treating cutaneous lymphoma, particularly in early stages.
research Dermatologist and Patient Perceptions of Treatment Success in Alopecia Areata and Evaluation of Clinical Outcome Assessments in Japan
Both dermatologists and patients in Japan agree that treatment success for alopecia areata is having 20% or less scalp hair loss.